Table 4.
Differences of patients with HCC under Milan, “Up-to seven,” and Hangzhou criteria.
| Variables | MC1-in (n = 108) |
MC-out and in-”Up-to-seven” (n =17) |
“Up-to-seven”-out and in-HZ (n = 28) |
P |
|---|---|---|---|---|
| Demographic data | ||||
| Age (years) | 53.5 (48.0, 59.0) | 54.0 (47.0, 57.0) | 53.0 (48.5, 56.5) | 0.721 |
| Sex Male Female |
93 (86.1%) 15 (13.9%) |
16 (94.1%) 1 (5.9%) |
27 (96.4%) 1 (3.6%) |
0.232 |
| BMI (kg/m2) | 24.3 (22.6, 26.7) | 24.8 (23.2, 26.9) | 24.8 (22.8, 28.8) | 0.311 |
| Etiology of liver disease CHB CHC Alcoholic Others |
75 (69.4%) 8 (7.4%) 17 (15.7%) 8 (7.4%) |
13 (76.5%) 0 (0.0%) 2 (11.8%) 2 (11.8%) |
21 (75.0%) 1 (3.6%) 5 (17.9%) 1 (3.6%) |
0.654 |
| MELD | 11.0 (8.0, 14.0) | 11.0 (9.0, 17.0) | 14.0 (9.5, 17.5) | 0.139 |
| Tumor characteristics | ||||
| AFP values (ng/ml) < 1000 > 1000 |
104 (96.3%) 4 (3.7%) |
17 (100.0%) 0 (0.0%) |
25 (89.3%) 3 (10.7%) |
0.181 |
| Tumor number ≦2 ≧3 |
103 (95.4%) 5 (4.6%) |
12 (70.6%) 5 (29.4%) |
16 (57.1%) 12 (42.9%) |
<0.001 |
| Max tumor diameter (cm) | 2.5 (1.5, 3.0) | 4.0 (3.5, 6.0) | 6.5 (5.5, 9.0) | <0.001 |
| Sum of tumor diameter (cm) | 2.5 (1.5, 3.5) | 6.0 (5.0, 6.0) | 8.5 (6.8, 10.7) | <0.001 |
| Pre-LT treatment of HCC | ||||
| Pre-LT RAF | 25 (23.1%) | 4 (23.5%) | 5 (17.9%) | 0.821 |
| Pre-LT TACE | 66 (61.1%) | 11 (64.7%) | 17 (60.7%) | 0.957 |
| Explant pathology | ||||
| Microvascular Invasion | 50 (46.3%) | 12 (70.6%) | 26 (92.9%) | <0.001 |
| TNM Stage I+ II III +IV |
99 (91.7%) 9 (8.3%) |
12 (70.6%) 5 (29.4%) |
12 (42.9%) 16 (57.1%) |
<0.001 |
MC, Milan criteria; HZ, Hangzhou criteria; BMI, body mass index; CHB, chronic hepatitis B; CHC, chronic hepatitis C; MELD, model for end-stage liver disease; AFP, alpha-fetoprotein; LT, liver transplantation; RAF, radiofrequency ablation; TACE, transhepatic arterial chemotherapy and embolization.